Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Safety of novel glaucoma surgery and the immediate postoperative period in stand alone and combined phacoemulsification (phaco) and CO2 laser-assisted sclerectomy surgery: class with mitomycin C

Search Title by author or title

Session Details

Session Title: Glaucoma II

Session Date/Time: Monday 12/09/2016 | 08:00-10:30

Paper Time: 10:24

Venue: Hall C4

First Author: : N.Shoham-Hazon ISRAEL

Co Author(s): :    N. Kovalyuck   S. Levartovsky                 

Abstract Details

Purpose:

To determine IOP control utilizing CLASS and Phaco-CLASS in the early postoperative period after surgery.

Setting:

Glaucoma, Cataract and Advanced Anterior Segment Unit, Barzilay University Medical Center, Ashkelon, Israel.

Methods:

A retrospective interventional non- randomized comparative chart review. Main outcome measures were same day IOP and 24 hours following surgery, as well at IOP at 1 month. We reviewed 16 eyes of 15 patients (one bilateral simultaneous stand alone CLASS).

Results:

Mean IOP preoperatively was 22.75±6.93 mmHg. Mean glaucoma medication classes preoperatively were 3.26±1.03 (range 2-5). Glaucoma severity ranged from mild field loss to advanced. Mean postoperative IOP same day was 12.68±9.1 (range 0-36 mmHg, p=0.000729) and 24 hours after surgery was 13.25±6.59 mmHg (range 4-27, p=0.000207). At one month mean IOP was 12.33±2.74 (p=0.000022). This review is ongoing and will present more results by time of presentation.

Conclusions:

CLASS was found to be safe and efficacious in the immediate postoperative period, same day and the first 24 hours after surgery. The IOP after one month was also highly significantly low from preoperative. No adverse events nor complications were noted, none of the patients required postoperative glaucoma medications or interventions.

Financial Disclosure:

... receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented., ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to previous